| ［1］ |
Qiu Y, Zhou X, Fu S, et al. Systematic review and meta⁃analysis of the association between metabolic syndrome and androgenetic alopecia［J］. Acta Derm Venereol, 2022,102:adv00645. doi: 10. 2340/actadv.v101.1012.
|
| ［2］ |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）［J］. 中华糖尿病杂志, 2021,13（4）:315⁃409. doi: 10. 3760/cma.j.cn115791⁃20210221⁃00095.
|
| ［3］ |
Liu J, Liu Q, Li Z, et al. Prevalence of metabolic syndrome and risk factors among Chinese adults: results from a population⁃based study ⁃ Beijing, China, 2017-2018［J］. China CDC Wkly, 2022,4（29）:640⁃645. doi: 10.46234/ccdcw2022.138.
|
| ［4］ |
Wang TL, Zhou C, Shen YW, et al. Prevalence of androgenetic alopecia in China: a community⁃based study in six cities［J］. Br J Dermatol, 2010,162（4）:843⁃847. doi: 10.1111/j.1365⁃2133. 2010.09640.x.
|
| ［5］ |
吴大兴, 吴丽峰, 杨宗兴. 雄激素性脱发与代谢综合征关系的meta分析［J］. 浙江大学学报（医学版）, 2014,43（5）:597⁃601.
|
| ［6］ |
Shimon SV, Soares GB, Miteva M. Association of metabolic abnormalities and non⁃scarring and scarring types of alopecia: a systematic review［J］. Arch Dermatol Res, 2024,316（7）:444. doi: 10.1007/s00403⁃024⁃03197⁃5.
|
| ［7］ |
Zhu H, Guo H, Gao Y, et al. A community⁃oriented survey on the association between androgenetic alopecia and metabolic syndrome in Chinese people［J］. Front Med （Lausanne）, 2022,9:1009578. doi: 10.3389/fmed.2022.1009578.
|
| ［8］ |
Natarelli N, Gahoonia N, Sivamani RK. Integrative and mechanistic approach to the hair growth cycle and hair loss［J］. J Clin Med, 2023,12（3）:893. doi: 10.3390/jcm12030893.
|
| ［9］ |
Zhang Y, Xu J, Jing J, et al. Serum levels of androgen⁃associated hormones are correlated with curative effect in androgenic alopecia in young men［J］. Med Sci Monit, 2018,24:7770⁃7777. doi: 10.12659/MSM.913116.
|
| ［10］ |
Lie C, Liew CF, Oon HH. Alopecia and the metabolic syndrome［J］. Clin Dermatol, 2018,36（1）:54⁃61. doi: 10.1016/j.clindermatol.2017.09.009.
|
| ［11］ |
Lucas⁃Herald AK, Touyz RM. Androgens and androgen receptors as determinants of vascular sex differences across the lifespan［J］. Can J Cardiol, 2022,38（12）:1854⁃1864. doi: 10. 1016/j.cjca.2022.09.018.
|
| ［12］ |
Unluhizarci K, Karaca Z, Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders［J］. World J Diabetes, 2021,12（5）:616⁃629. doi: 10.4239/wjd.v12.i5.616.
|
| ［13］ |
Sanke S, Chander R, Jain A, et al. A comparison of the hormonal profile of early androgenetic alopecia in men with the phenotypic equivalent of polycystic ovarian syndrome in women［J］. JAMA Dermatol, 2016,152（9）:986⁃991. doi: 10.1001/jamadermatol. 2016.1776.
|
| ［14］ |
Melnik BC, Schmitz G. Role of insulin, insulin⁃like growth factor⁃1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris［J］. Exp Dermatol, 2009,18（10）:833⁃841. doi: 10.1111/j.1600⁃0625.2009.00924.x.
|
| ［15］ |
Tan L, Liu Y, Liu J, et al. Association between insulin resistance and uncontrolled hypertension and arterial stiffness among US adults: a population⁃based study［J］. Cardiovasc Diabetol, 2023,22（1）:311. doi: 10.1186/s12933⁃023⁃02038⁃5.
|
| ［16］ |
Igbekele AE, Jia G, Hill MA, et al. Mineralocorticoid receptor activation in vascular insulin resistance and dysfunction［J］. Int J Mol Sci, 2022,23（16）:8954. doi: 10.3390/ijms23168954.
|
| ［17］ |
Deng Z, Chen M, Liu F, et al. Androgen receptor⁃mediated paracrine signaling induces regression of blood vessels in the dermal papilla in androgenetic alopecia［J］. J Invest Dermatol, 2022,142（8）:2088⁃2099.e9. doi: 10.1016/j.jid.2022.01.003.
|
| ［18］ |
Parwani K, Mandal P. Role of advanced glycation end products and insulin resistance in diabetic nephropathy［J］. Arch Physiol Biochem, 2023,129（1）:95⁃107. doi: 10.1080/13813455.2020. 1797106.
|
| ［19］ |
Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage［J］. Nature, 2000,404（6779）:787⁃790. doi: 10.1038/35008121.
|
| ［20］ |
Soro⁃Paavonen A, Zhang WZ, Venardos K, et al. Advanced glycation end⁃products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase［J］. J Hypertens, 2010,28（4）:780⁃788. doi: 10.1097/HJH.0b013e328335043e.
|
| ［21］ |
Cheng M, Yang Z, Qiao L, et al. AGEs induce endothelial cells senescence and endothelial barrier dysfunction via miR⁃1⁃3p/MLCK signaling pathways［J］. Gene, 2023,851:147030. doi: 10.1016/j.gene.2022.147030.
|
| ［22］ |
Mustafa AI, Abel Halim W, Eman F, et al. Metabolic syndrome in androgenetic alopecia patients; Is serum regulated on activation, normal T⁃cell expressed and secreted the missing link?［J］. J Cosmet Dermatol, 2021,20（7）:2270⁃2276. doi: 10.1111/jocd.13802.
|
| ［23］ |
Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle⁃aged women［J］. J Am Acad Dermatol, 1996,35（6）:899⁃906. doi: 10.1016/s0190⁃9622（96）90113⁃9.
|
| ［24］ |
Ramos PM, Brianezi G, Martins AC, et al. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation［J］. Int J Cosmet Sci, 2016,38（6）:651⁃654. doi: 10.1111/ics.12341.
|
| ［25］ |
Merlotto MR, Ramos PM, Miot HA. Pattern hair loss: assessment of microinflammation in miniaturized and terminal hair follicles through horizontal histologic sections［J］. J Am Acad Dermatol, 2020,83（2）:e145⁃e146. doi: 10.1016/j.jaad.2020.03.119.
|
| ［26］ |
Wang S, Xu S, Wang S, et al. Risk factors and lipid metabolism characteristics of early⁃onset male androgenetic alopecia: a pilot study［J］. J Cosmet Dermatol, 2024,23（9）:3038⁃3044. doi: 10.1111/jocd.16371.
|
| ［27］ |
Dawoud NM, Dawoud MM, El Hefnawy SM, et al. Circulating and/or cutaneous irisin resistance: a novel link among androgenetic alopecia, comorbid metabolic syndrome and cardiovascular risks［J］. J Cosmet Dermatol, 2023,22（9）:2584⁃2597. doi: 10.1111/jocd.15760.
|
| ［28］ |
Kim H, Wrann CD, Jedrychowski M, et al. Irisin mediates effects on bone and fat via αV integrin receptors［J］. Cell, 2018,175（7）:1756⁃1768.e17. doi: 10.1016/j.cell.2018.10.025.
|
| ［29］ |
Raschke S, Eckel J. Adipo⁃myokines: two sides of the same coin--mediators of inflammation and mediators of exercise［J］. Mediators Inflamm, 2013,2013:320724. doi: 10.1155/2013/320724.
|
| ［30］ |
Cheng ZB, Huang L, Xiao X, et al. Irisin in atherosclerosis［J］. Clin Chim Acta, 2021,522:158⁃166. doi: 10.1016/j.cca.2021.08. 022.
|
| ［31］ |
中华医学会整形外科学分会中国雄激素性脱发诊断与治疗指南制订工作组, 整形美容专业国家级医疗质量控制中心, 中国整形美容协会毛发医学分会, 等. 2023中国临床实践指南：雄激素性脱发诊断与治疗［J］. 中华整形外科杂志, 2024,40（1）:1⁃20. doi: 10.3760/cma.j.cn114453⁃20231029⁃00156.
|
| ［32］ |
中华医学会老年医学分会老年内分泌代谢疾病学组中国老年代谢综合征药物治疗专家共识（2022）编写组. 中国老年人代谢综合征药物治疗专家共识（2022）［J］. 中华老年医学杂志, 2022,41（9）:1011⁃1027. doi: 10.3760/cma.j.issn.0254⁃9026.2022.09.001.
|
| ［33］ |
Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome ⁃ a new definition and management guidelines: a joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons［J］. Arch Med Sci, 2022,18（5）:1133⁃1156. doi: 10.5114/aoms/152921.
|
| ［34］ |
Krysiak R, Kowalcze K, Okopień B. Impaired metabolic effects of metformin in men with early⁃onset androgenic alopecia［J］. Pharmacol Rep, 2022,74（1）:216⁃228. doi: 10.1007/s43440⁃021⁃00347⁃8.
|
| ［35］ |
Drucker DJ. GLP⁃1 physiology informs the pharmacotherapy of obesity［J］. Mol Metab, 2022,57:101351. doi: 10.1016/j.molmet. 2021.101351.
|
| ［36］ |
Desai DD, Sikora M, Nohria A, et al. GLP⁃1 agonists and hair loss: a call for further investigation［J］. Int J Dermatol, 2024,63（9）:1128⁃1130. doi: 10.1111/ijd.17246.
|
| ［37］ |
Burke O, Sa B, Cespedes DA, et al. Glucagon⁃like peptide⁃1 receptor agonist medications and hair loss: a retrospective cohort study［J］. J Am Acad Dermatol, 2025,92（5）:1141⁃1143. doi: 10.1016/j.jaad.2025.01.046.
|
| ［38］ |
Gordon ER, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss［J］. JAAD Case Rep, 2024,50:123⁃125. doi: 10.1016/j.jdcr. 2024.06.001.
|
